Medtronic reported improving results yesterday, and reiterated its FY18 revenue and EPS outlook despite production disruptions. This was well perceived by the market, as MDT had become a low expectation story in the recent quarters. Price target unchanged at $88. Continue reading “Medtronic 2Q18 results: relief rally yesterday as management showed optimism for the rest of the year”